136 related articles for article (PubMed ID: 16411388)
1. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events.
Kuhle S; Massicotte P; Dinyari M; Vegh P; Mitchell D; Marzinotto V; Chan A; Pieniaszek H; Mitchell LG
Thromb Haemost; 2005 Dec; 94(6):1164-71. PubMed ID: 16411388
[TBL] [Abstract][Full Text] [Related]
2. Higher Tinzaparin Dosing Is Needed to Achieve Target Anti-Xa Levels in Pediatric Cardiac Intensive Care Patients.
Roeleveld PP; van der Hoeven A; de Wilde RB; Eikenboom J; Smiers FJ; Bunker-Wiersma HE
Pediatr Crit Care Med; 2016 Mar; 17(3):203-9. PubMed ID: 26808621
[TBL] [Abstract][Full Text] [Related]
3. Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study.
Norris LA; Bonnar J; Smith MP; Steer PJ; Savidge G
Thromb Haemost; 2004 Oct; 92(4):791-6. PubMed ID: 15467910
[TBL] [Abstract][Full Text] [Related]
4. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days.
Siguret V; Pautas E; Février M; Wipff C; Durand-Gasselin B; Laurent M; Andreux JP; d'Urso M; Gaussem P
Thromb Haemost; 2000 Nov; 84(5):800-4. PubMed ID: 11127859
[TBL] [Abstract][Full Text] [Related]
5. Weight-adjusted dosing of tinzaparin in pregnancy.
Gibson PS; Newell K; Sam DX; Mansoor A; Jiang X; Tang S; Ross S
Thromb Res; 2013 Feb; 131(2):e71-5. PubMed ID: 23245654
[TBL] [Abstract][Full Text] [Related]
6. Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*.
Schloemer NJ; Abu-Sultaneh S; Hanson SJ; Yan K; Hoffmann RG; Punzalan RC; Havens PL
Pediatr Crit Care Med; 2014 Sep; 15(7):e294-9. PubMed ID: 24901803
[TBL] [Abstract][Full Text] [Related]
7. [Heparins].
Marbet GA
Ther Umsch; 2003 Jan; 60(1):10-3. PubMed ID: 12638471
[TBL] [Abstract][Full Text] [Related]
8. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism.
Wilson SJ; Wilbur K; Burton E; Anderson DR
Haemostasis; 2001; 31(1):42-8. PubMed ID: 11408748
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the age-dependent dosing recommendations for the administration of daily tinzaparin in children with thrombosis.
Musgrave KM; Webber K; Murphy P; Avery P; Biss TT
J Thromb Haemost; 2017 Dec; 15(12):2361-2366. PubMed ID: 28976613
[TBL] [Abstract][Full Text] [Related]
10. Tinzaparin versus dalteparin for periprocedure prophylaxis of thromboembolic events in hemodialysis patients: a randomized trial.
Rodger MA; Ramsay T; MacKinnon M; Westphal M; Wells PS; McCormick B; Knoll G
Am J Kidney Dis; 2012 Sep; 60(3):427-34. PubMed ID: 22480794
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates.
Jeske W; Fareed J
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():41-7. PubMed ID: 15085465
[TBL] [Abstract][Full Text] [Related]
12. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.
Hainer JW; Sherrard DJ; Swan SK; Barrett JS; Assaid CA; Fossler MJ; Cox DS; Williams RM; Pittenger AL; Stephenson CA; Hua TA
Am J Kidney Dis; 2002 Sep; 40(3):531-8. PubMed ID: 12200805
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of enoxaparin dosing requirements in infants and children. Better dosing to achieve therapeutic levels.
Bauman ME; Belletrutti MJ; Bajzar L; Black KL; Kuhle S; Bauman ML; Patricia Massicotte M
Thromb Haemost; 2009 Jan; 101(1):86-92. PubMed ID: 19132193
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of once daily low molecular weight heparin (tinzaparin sodium) in high risk pregnancy.
Ní Ainle F; Wong A; Appleby N; Byrne B; Regan C; Hassan T; Milner M; Sullivan AO; White B; O'Donnell J
Blood Coagul Fibrinolysis; 2008 Oct; 19(7):689-92. PubMed ID: 18832911
[TBL] [Abstract][Full Text] [Related]
15. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study.
Mahé I; Aghassarian M; Drouet L; Bal Dit-Sollier C; Lacut K; Heilmann JJ; Mottier D; Bergmann JF
Thromb Haemost; 2007 Apr; 97(4):581-6. PubMed ID: 17393021
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis.
Barrett JS; Gibiansky E; Hull RD; Planès A; Pentikis H; Hainer JW; Hua TA; Gastonguay M
Int J Clin Pharmacol Ther; 2001 Oct; 39(10):431-46. PubMed ID: 11680668
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers.
Fossler MJ; Barrett JS; Hainer JW; Riddle JG; Ostergaard P; van der Elst E; Sprogel P
Am J Health Syst Pharm; 2001 Sep; 58(17):1614-21. PubMed ID: 11556655
[TBL] [Abstract][Full Text] [Related]
18. A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?
Berresheim M; Wilkie J; Nerenberg KA; Ibrahim Q; Bungard TJ
Thromb Res; 2014 Dec; 134(6):1234-40. PubMed ID: 25450535
[TBL] [Abstract][Full Text] [Related]
19. [Monitoring of tinzaparin in a ten day treatment dose in elderly patients].
Pautas E; Siguret V; d'Urso M; Laurent M; Gaussem P; Février M; Durand-Gasselin B
Rev Med Interne; 2001 Feb; 22(2):120-6. PubMed ID: 11234669
[TBL] [Abstract][Full Text] [Related]
20. Empirically Reduced Dosages of Tinzaparin in Patients with Moderate-to-Severe Renal Insufficiency Lead to Inadequate Anti-Xa Levels.
Olie RH; Meertens NEL; Henskens YMC; Ten Cate H
Nephron; 2017; 137(2):113-123. PubMed ID: 28662505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
